Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNK01 + trastuzumab
- Development stage
- Unknown
- Lead developer
- NKGen Biotech, Inc.
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**SNK01 + trastuzumab** is an investigational combination therapy comprising two distinct agents: SNK01 (also known as troculeucel), an autologous, ex vivo expanded, enhanced-activity, non-genetically modified natural killer (NK) cell therapy, and trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2). SNK01 utilizes autologous NK cells with increased cytotoxicity for improved immunotherapeutic effect. Trastuzumab binds HER2 and mediates antitumor effects through direct receptor blockade and antibody-dependent cellular cytotoxicity (ADCC). This combination has been developed for advanced/metastatic HER2-positive cancers that are refractory to conventional treatments. Early clinical studies focused on safety, tolerability, and preliminary efficacy in advanced malignancies expressing HER2, with clinical development led by NKGen Biotech. The mechanism of action is hypothesized to include enhanced ADCC from synergistic activity between SNK01 NK cells and trastuzumab[1][2][4][5].
- Brand names
- Herceptin
- Other names
- troculeucel + trastuzumabSuper Natural Killer Cells 01 + trastuzumabautologous non-genetically modified natural killer cells with enhanced cytotoxicity + trastuzumab
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on SNK01 + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNK01 + trastuzumab.